NN8640-4515 A multi-national, multi-centre, prospective, single-arm, observational, non-interventional post-authorisation safety study to investigate long-term safety of Sogroya® (somapacitan) in adults with growth hormone deficiency (AGHD) under routine clinical practice

First published 20/04/2023

Last updated 23/04/2024

EU PAS number:

EUPAS104526

Study

Ongoing

Documents

Study protocol

Initial protocol

4515 16-1-01 protocol eu-pas-reg-redacted

English (1.08 MB - PDF)View document

Study results

Study report

4515 regulatory pass progress report no. 1 eu-pas-reg redacted

English (387.35 KB - PDF)View document

4515 regulatory pass progress report no. 2 eu-pas-reg redacted

English (436.97 KB - PDF)View document

Other information

Study, other information

4515 regulatory pass progress report no. 2 eu-pas-reg redacted.pdf

English (436.97 KB - PDF)View document

ENCePP Seal

ENCePP Seal documents

Secondary tabs